HEALTHCARE

13 Dec 2019

Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting

- Four-Year Data Continue to Show Superior Progression-Free Survival of ADCETRIS in Combination with AVD when Compared to ABVD in Frontline Advanced Hodgkin Lymphoma with 31 Percent Reduction in the Risk of Progression or Death -

- Additional Analysis from ECHELON-2 Phase 3"...

Continue Reading

12 Dec 2019

Egypt's Rameda Pharmaceutical shares end 4.7% lower in debut trading

Cairo: Shares in Egyptian generic drug maker Rameda Pharmaceutical closed down 4.7% on Wednesday on their first day of trading, but still finished off their session lows.

The shares, which fell by as much 13.1%"...

Continue Reading

12 Dec 2019

Final results from the NuProtect study demonstrating efficacy of Nuwiq® (simoctocog alfa) in previously untreated patients (PUPs) presented at ASH 2019

Octapharma has announced today that the final results from the NuProtect study, the largest prospective study of a single factor VIII (FVIII) product in true PUPs with severe haemophilia A, were presented today in an oral presentation at the American Society of Hematology (ASH) 2019 Annual"...

Continue Reading

11 Dec 2019

Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 2019

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented nine hematology poster presentations at the 61st American Society of Hematology (ASH) Annual Meeting that underscore its commitment to advancing treatments for rare bleeding disorders by incorporating real-world data and developing innovative adeno-associated virus (AAV) gene therapies. Understanding Real-World Evidence to Advance Patient-Centric Innovation in Bleeding Disorders Real-world evidence from studies across many of Takeda’s portfolio of treatments for hemophilia demonstrate the cost savings and patient benefits resulting from ongoing......

Continue Reading

11 Dec 2019

Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting on Saturday, December 7, 2019 in Orlando, Florida. TOURMALINE-AL1 is a Phase 3, randomized clinical trial evaluating the effect of NINLAROTM (ixazomib) in combination with dexamethasone in patients with relapsed or refractory systemic light-chain (AL) amyloidosis. The TOURMALINE-AL1 trial did not meet the first of the two primary endpoints of significant improvement in overall hematologic response, as reported in June 2019. Hematologic......

Continue Reading

09 Dec 2019

Rameda plans to introduce new drugs for the digestive system, diabetes, nerves, and antibiotics

The Tenth of Ramadan Company for Pharmaceutical Industries and Diagnostic Products (Rameda) is to produce new drugs during 2020 that treat the digestive system, neurological problems, and antibiotics for young and old patients, as well as supplements and modern medicines for diabetes.

"...

Continue Reading

09 Dec 2019

Galderma Investigational Therapy Nemolizumab Granted FDA Breakthrough Therapy Designation for the Treatment of Patients Suffering from Prurigo Nodularis

Galderma today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational therapy nemolizumab for the treatment of pruritus associated with prurigo nodularis.

Prurigo"...

Continue Reading

05 Dec 2019

Rameda Pharmaceutical's share placement covered 1.17 times

Cairo: A private share placement by Egypt’s Rameda Pharmaceutical on the Egyptian stock exchange was covered 1.17 times, the company said on Wednesday.

Rameda has offered 49% of its shares on the exchange"...

Continue Reading

05 Dec 2019

UAE Ministry of Health Collaborates with Vocera to Improve Care Team Communication and Optimise Patient Safety

Vocera Communications, Inc. (NYSE:VCRA), a recognised leader in clinical communication and workflow solutions, today announced that the Ministry of Health and Prevention of the United Arab Emirates plans to standardise care team communication using Vocera technology. An expected enterprise-wide deployment of the Vocera smartphone app and the new Vocera Smartbadge is part of a strategic alignment aimed at improving care team collaboration, optimising operational efficiency, and elevating patient care and safety. “Our partnership with Vocera and the implementation of the company’s unique solutions represents a breakthrough in our digital......

Continue Reading

03 Dec 2019

Gen Re and PAI Health Take Strategic Partnership to Next Level

Decades of evidence have proven cardiorespiratory fitness to be a leading predictor of longevity and future health. Yet it is one that has been largely overlooked within insurance customer health profiles. With the signing of the exclusive agreement between leading global reinsurer, Gen"...

Continue Reading
Found articles: - Pages  
Contact US | Powered by CNPHUB.com - All Rights Reserved